INFU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
InfuSystem Holdings Inc. (INFU) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has demonstrated strong financial performance, positive analyst sentiment, and growth in key segments. While the RSI indicates the stock is overbought, the long-term growth potential outweighs this short-term technical indicator.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 80.638, signaling the stock is overbought. The price is above key resistance levels (R1: 8.902, R2: 9.348), suggesting strong upward momentum. Moving averages are converging, which could indicate a potential trend continuation.
Strong Q4 2025 financial performance with 7% YoY revenue growth and 118.22% YoY net income growth.
Positive analyst sentiment with increased price targets from Lake Street ($17.
and Roth Capital ($15).
Record revenues for the seventh consecutive year, driven by growth in Oncology, Wound Care, and Device Solutions segments.
Hedge funds are selling, with a significant 1158.53% increase in selling activity over the last quarter.
RSI indicates overbought conditions, which may lead to short-term price corrections.
In Q4 2025, revenue increased by 7.04% YoY to $36.23M, net income surged by 118.22% YoY to $2.036M, EPS rose by 150% YoY to $0.10, and gross margin improved by 5.16% YoY to 55.82%. The company achieved record revenues for the seventh consecutive year.
Analysts are bullish on INFU. Lake Street raised the price target to $17.50, citing confidence in management and high ROIC potential. Roth Capital increased the price target to $15, highlighting above-consensus Q4 results and growth in key business segments.
